BofA analyst Andrew Obin raised the firm’s price target on Emerson (EMR) to $191 from $165 and keeps a Buy rating on the shares. Orders acceleration was “the star of 1QF26 results,” says the analyst, who now forecasts FY26 adjusted EPS of $6.58, up 10% year-over-year and slightly above raised guidance of $6.40-$6.55.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMR:
- Emerson price target raised to $174 from $165 at Citi
- Emerson price target raised to $160 from $145 at Wells Fargo
- Sell Rating Maintained Amid Growth Headwinds, Unreliable Order Signals, and Second-Half Execution Risks
- Emerson reports Q1 adjusted EPS $1.46, consensus $1.41
- Emerson sees FY26 adjusted EPS $6.40-$6.55, consensus $6.48